Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIUPRES-500 vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diupres-500 is a combination of chlorothiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid. Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion. Reserpine depletes catecholamines from central and peripheral nerve terminals by blocking vesicular monoamine transporter 2 (VMAT2), leading to decreased sympathetic outflow and vasodilation.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Essential hypertension,Edema associated with congestive heart failure, hepatic cirrhosis, and renal dysfunction
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Oral, 1 tablet (hydrochlorothiazide 50 mg + reserpine 0.125 mg) once daily, increased up to 2 tablets per day if needed.
250 mg orally twice daily
Reserpine: 50-100 hours (prolonged; clinical effect persists for days due to irreversible MAO depletion). Hydrochlorothiazide: 6-15 hours (biphasic; terminal phase reflects renal elimination).
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Chlorothiazide is not metabolized and is excreted unchanged in urine. Reserpine is extensively metabolized in the liver via CYP450 enzymes to inactive metabolites.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal: ~50% (primarily hydrochlorothiazide), Fecal: ~50% (primarily reserpine).
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Reserpine: ~96% (albumin). Hydrochlorothiazide: ~68% (albumin).
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Reserpine: 4-8 L/kg (extensive tissue binding, especially lipid-rich and CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: Reserpine ~50% (variable due to first-pass metabolism); Hydrochlorothiazide ~65-70% (dose-dependent).
70-90% (oral); 100% (IV).
GFR 30-50 m L/min: use with caution, reduce dose if needed. GFR <30 m L/min: contraindicated.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: no adjustment. Child-Pugh B or C: contraindicated due to risk of hepatic encephalopathy.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not recommended; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Initiate at lowest dose (50 mg hydrochlorothiazide + 0.125 mg reserpine) once daily; monitor electrolytes, renal function, and CNS depression.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Electrolyte imbalance: Monitor potassium, sodium, magnesium; hypokalemia increases risk of digitalis toxicity,Mental depression: Reserpine may cause severe depression, especially in patients with history,Sulfonamide cross-sensitivity: Chlorothiazide may cause allergic reactions in patients with sulfonamide allergy,Azotemia: May precipitate renal impairment in patients with kidney disease,Orthostatic hypotension: Common with reserpine, especially after initial doses
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to chlorothiazide, reserpine, or sulfonamide-derived drugs,Anuria,Active peptic ulcer disease,Ulcerative colitis,History of mental depression (especially with suicidal tendencies),Electroconvulsive therapy,Pheochromocytoma
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid excessive intake of high-potassium foods (e.g., bananas, oranges, spinach) due to increased potassium retention risk with hydrochlorothiazide. Limit alcohol consumption as it may enhance blood pressure-lowering effects and cause dizziness. Maintain adequate hydration but avoid potassium-containing salt substitutes.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
First trimester: Risk of fetal hydantoin syndrome (craniofacial defects, hypoplastic nails, growth deficiency). Second trimester: Increased risk of neural tube defects, congenital heart defects. Third trimester: Risk of neonatal hemorrhage and hepatic enzyme induction.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Excreted in breast milk; M/P ratio approximately 0.2-0.4. Consider risk of infant sedation and poor feeding. Weigh benefits of breastfeeding against potential adverse effects.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Increased clearance due to hepatic induction and increased volume of distribution; may require up to 50% dose increase. Monitor free phenytoin levels as protein binding decreases. Adjust dose to maintain therapeutic levels.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
DIUPRES-500 contains hydrochlorothiazide 50 mg and reserpine 0.125 mg. Monitor serum potassium and renal function regularly. Reserpine may cause bradycardia and depression; use with caution in patients with history of peptic ulcer disease. Avoid abrupt discontinuation due to risk of withdrawal hypertension.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take this medication exactly as prescribed, usually once daily in the morning.,Do not stop taking this medication suddenly without consulting your doctor.,This drug may make you urinate more frequently; avoid taking it before bedtime.,Report any symptoms of depression, unusual fatigue, or slow heart rate to your doctor.,Avoid prolonged sun exposure and use sunscreen; this medication can increase sensitivity to sunlight.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIUPRES-500 vs ALDOCLOR-250, answered by our medical review team.
DIUPRES-500 is a Antihypertensive Combination that works by Diupres-500 is a combination of chlorothiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid. Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion. Reserpine depletes catecholamines from central and peripheral nerve terminals by blocking vesicular monoamine transporter 2 (VMAT2), leading to decreased sympathetic outflow and vasodilation.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIUPRES-500 and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIUPRES-500 is: Oral, 1 tablet (hydrochlorothiazide 50 mg + reserpine 0.125 mg) once daily, increased up to 2 tablets per day if needed.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIUPRES-500 and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIUPRES-500 is classified as Category C. First trimester: Risk of fetal hydantoin syndrome (craniofacial defects, hypoplastic nails, growth deficiency). Second trimester: Increased risk of neural tube defects, congenital . ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.